Trial intelligence / Profile preview

Gastrointestinal behavior of dasatinib in healthy volunteers

2019-000460-21Phase 4Terminated

Sponsor
KU Leuven
Start
Mar 2019
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 4 trial of dasatinib (2 arms), sponsored by KU Leuven. Primary endpoint: Gastrointestinal behavior of dasatinib. Started Mar 2019; status: terminated.

02

Drugs

dasatinib

Beyond the preview

Go deeper on 2019-000460-21.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2019-000460-21.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call